Recommendations for Adopting Standard Conditions and Analytical Procedures in the Measurement of Serum Fructosamine Concentration

Hill, Robert P.; Hindle, E J; Howey, J. E. A.; Lemon, Marius; Lloyd, D. R.

doi:10.1177/000456329002700502

Cited by 27 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This should be borne in mind when interpreting glycated protein results in uraemic diabetic subjects. We would agree in principle with the conclusion of Hill et al [26], who suggest that in subjects with low serum albumin a n d /o r large losses of albumin, abnormal albumin turnover rate causes both absolute and corrected fructo samine concentrations to be inaccurate reflections of glycaemic control. However, corrected fructosamine may be a better marker than corrected glycated albumin in CAPD patients since it includes the component of non-albumin glycated proteins.…”

Section: Discussionsupporting

confidence: 91%

“…Fructosamine determination can suffer from inter ference due to non-specific reducing substances [26] and Morgan et al [11] have suggested that this is the cause of the raised fructosamine in haemodialysis patients. They found a significant decrease in serum fructosamine following haemodialysis, suggesting non-specific interference in the assay from dialysable compounds.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients

Lamb

Venton²,

Cattell³

et al. 1993

Nephron

View full text Add to dashboard Cite

The effect of uraemia on protein glycation was studied by measuring glycated albumin and fructosamine in 50 non-diabetic dialysis patients (31 continuous ambulatory peritoneal dialysis, CAPD, 19 haemodialysis). After correction for serum albumin concentration, glycated albumin (g/l00 g) was increased in the haemodialysis group (1.94 ± 0.40) compared with both CAPD patients (1.46 ± 0.37; p < 0.001) and controls (1.52 ± 0.29; p < 0.001), but did not differ between CAPD patients and controls (p > 0.05). Serum fructosamine, corrected for either serum albumin or total protein concentration (μmol/100 g), was raised in CAPD (828 ± 90, 386 ± 41, respectively) and haemodialysis patients (802 ± 123, 391 ± 42, respectively) compared with controls (609 ± 69, 332 ± 27, respectively; p < 0.0001 in all cases), but did not differ between the two dialysis groups (p > 0.05). A single haemodialysis cycle had no effect on the measurement of glycated albumin or fructosamine (p > 0.05). The results confirm that glycated protein levels are generally raised in dialysis patients. In CAPD patients, altered albumin metabolism resulting from large peritoneal losses is likely to have caused a decrease in the amount of albumin glycated, an effect less apparent on the concentration of fructosamine because of the additional contribution of glycated globulins.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients

Lamb

Venton²,

Cattell³

et al. 1993

Nephron

View full text Add to dashboard Cite

show abstract

“…Furthermore, even when the total protein concentration is normal, dysproteinemias (i.e., qualitative changes in serum protein composition) may affect fructosamine values; this cannot be corrected by simple adjustment by protein concentration (172). Finally, Hill et al (159) concluded that while in a given population a relationship between serum fructosamine and protein may be apparent, the clinical utility of routine fructosamine correction has not been clearly established.…”

Section: Glycated Serum Proteinsmentioning

confidence: 99%

Tests of Glycemia in Diabetes

et al. 2004

View full text Add to dashboard Cite

“…It has since been recommended that a reagent pH of 10'35 and incubation time of at least 10min be used to reduce non-specific interferences. 12 These recommendations are followed in the Roche kits used in this study. It is therefore likely that non-specific reducing activity was contributing to the greater variation found by Howey et al:"…”

Section: Discussionmentioning

confidence: 99%

Biological Variation in Glycated Proteins

Davie¹,

Whiting

Gould

1993

Ann Clin Biochem

View full text Add to dashboard Cite

SUMMARY. The high degree of individuality in the fructosamine assay has been ascribed to non-specific interferences in the assay. To investigate this, we measured the biological variability of 10 non-diabetic subjects using the fructosamine assay, the new fructosamine plus assay, glycated albumin and glycated total plasma proteins by affinity chromatography.The total variation of the two fructosamine assays was half that of the affinity chromatography assays. This was mainly due to the greater analytical imprecision of the affinity chromatography assays. The resulting high index of heterogeneity for both affinity methods makes it difficult to assess the significance of changes in serial results.The within-subject variation made a small contribution to the total variation for all the assays, and was particularly low for the fructosamine assays. This suggests that any non-specific component makes a constant contribution to the measured fructosamine activity in non-diabetic subjects.The fructosamine assays therefore have significant advantages over the affinity chromatography methods as indices of medium-term glycaernic control.

show abstract

Recommendations for Adopting Standard Conditions and Analytical Procedures in the Measurement of Serum Fructosamine Concentration

Cited by 27 publications

References 39 publications

Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients

Serum Glycated Albumin and Fructosamine in Renal Dialysis Patients

Tests of Glycemia in Diabetes

Biological Variation in Glycated Proteins

Contact Info

Product

Resources

About